GPT and liver disorder: Patients of this control group should not have reported any DS consumption within the previous 60 days but fulfil the regulatory criteria for hepatotoxicity, e.g., serum ALT >4N and total bilirubin >2N, with a valid diagnosis and established cause of the patients’ liver disease for comparison.